Table 2.
Final diagnoses
| Male (n = 167) | Female (n = 107) | All (n = 274) | |
|---|---|---|---|
| No amyloidosis | 80 (48%) | 62 (58%) | 142 (52%) |
| TTR mutation | 22 (28%) | 31 (50%) | 53 (37%) |
| No TTR mutation | 58 (72%) | 31 (50%) | 89 (63%) |
| Amyloidosis | 87 (52%) | 45 (42%) | 132 (48%) |
| ATTRv amyloidosis | 82 (94%) | 41 (91%) | 123 (93%) |
| Dx before 2006 | 10 (12%) | 9 (22%) | 19 (16%) |
| ATTRV30M | 69 (84%) | 31 (76%) | 100 (81%) |
| Other mutationa | 3 (4%) | 1 (2%) | 4 (3%) |
| ATTRwt amyloidosis | 1 (1%) | 0 (0%) | 1 (1%) |
| AL amyloidosis | 4 (5%) | 3 (7%) | 7 (5%) |
| Localized | 3 (75%) | 3 (100%) | 6 (86%) |
| Systemic | 1 (25%) | 0 (0%) | 1 (14%) |
| Gelsolin amyloidosis | 0 (0%) | 1 (2%) | 1 (1%) |
aH88R, A45S, V122I and A97S; AL, amyloid light chain; ATTRv, variant transthyretin amyloidosis; ATTRV30M, transthyretin amyloidosis caused by the TTR V30M mutation; ATTRwt, wild-type transthyretin amyloidosis; Dx, diagnosis; TTR, transthyretin gene. Percentages are shown as column percentage within each heading/subheading